Johanna Mylet - Mar 1, 2024 Form 4 Insider Report for Poseida Therapeutics, Inc. (PSTX)

Role
Chief Financial Officer
Signature
/s/ Harry J.Leonhardt, Attorney-in-Fact
Stock symbol
PSTX
Transactions as of
Mar 1, 2024
Transactions value $
-$74,716
Form type
4
Date filed
3/4/2024, 05:29 PM
Previous filing
Mar 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PSTX Common Stock Award $0 +80.7K +43.97% $0.00 264K Mar 1, 2024 Direct F1, F2
transaction PSTX Common Stock Tax liability -$74.7K -18.1K -6.84% $4.13 246K Mar 1, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PSTX Employee Stock Option (Right to Buy) Award $0 +112K $0.00 112K Mar 1, 2024 Common Stock 112K $4.13 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments.
F2 Includes 3,000 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on March 20, 2023 and 3,000 shares acquired by the Reporting Person under the ESPP on September 20, 2023.
F3 Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on March 1, 2022 and March 1, 2023.
F4 12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.